^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DS-1103

    i
    Other names: DS 1103a, DS-1103, DS-1103a, DS1103, DS 1103, DS1103a
    Associations

    News

    Trials
    Company:
    Daiichi Sankyo
    Drug class:
    SIRPA antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates. (PubMed, PLoS One)
    To this end, DS-1103a, a newly developed anti-human SIRPα antibody (Ab), was assessed for the potential combination benefit with datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), DXd-ADCs targeting human trophoblast cell-surface antigen 2 and human epidermal growth factor receptor 2, respectively. Furthermore, in syngeneic mouse models, both Dato-DXd and T-DXd combination with anti-mSIRPα Ab showed stronger anti-tumor activity over the monotherapies. Taken together, this study provides a preclinical rationale of novel therapies for solid tumors combining SIRPα-CD47 blockers with DXd-ADCs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • SIRPA (Signal Regulatory Protein Alpha)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • datopotamab deruxtecan (DS-1062a) • DS-1103
    over1year
    A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors (ESMO 2023)
    Primary endpoints include the safety and tolerability of the combination in both parts, determining the recommended dose of DS-1103a in combination for expansion in Part 1, and assessing the objective response rate in Part 2. Secondary endpoints include the antitumor activity of DS-1103a + T-DXd, pharmacokinetic profile of DS-1103a, and incidence of antidrug antibodies against DS-1103a.
    Clinical • P1 data • IO biomarker • Metastases
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    HER-2 mutation • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103
    over1year
    A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=78, Recruiting, Daiichi Sankyo, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 mutation • HER-2 expression • ER positive + PGR positive
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103
    over1year
    A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=78, Not yet recruiting, Daiichi Sankyo, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 mutation • HER-2 expression • ER positive + PGR positive
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • DS-1103